摘要
目的:研究肾移植受者孕烷X受体(PXR-C24381A)基因多态性与他克莫司(FK506)给药剂量的关系。方法:采用聚合酶链反应(PCR)产物直接测序法对60例肾移植术后受者进行PXR-C24381A基因分型,采用酶联免疫吸附分析法(ELISA法)测定FK506的血药浓度,比较不同基因型患者FK506血药浓度与给药剂量比值(C/D值)的差异。结果:肾移植受者PXR-C24381A等位基因C的频率为75%,A的频率为25%。C/A基因型与C/C基因型患者C/D值显著高于A/A基因型患者(P<0.05)。结论:肾移植受者PXR-C24381A基因多态性与FK506血药浓度具有相关性,A/A基因型患者拟取得相似的血药浓度需要比C/A和C/C基因型患者服用更高剂量的FK506。
OBJECTIVE： To study the relationship between pregnane X receptor （PXR-C24381A） genetic polymorphism and dosage of tacrolimus （FKS06） in kidney-transplanted patients. METHODS： The PXR genotypes of 60 kidney-transplanted patients were determined by PCR- direct sequencing. Blood concentration of FKS06 was measured by ELISA. The blood concentration of FK506 in patients with different genotypes was compared with dosage （C/D ratio）. RESULTS： The frequency of PXR-C24381A al- lele C was 75%, and that of allele A was 25%. C/D ratio of patients with A/A genotype was significantly lower than those with C/ A genotype or C/C genotype （P〈0.05）. CONCLUSIONS： PXR-C24381A polymorphism is correlated with the blood concentration of FKS06 in kidney-transplanted patients. If the same blood concentration of FK506 is presented in three genotypes, patients with A/ A genotype should take higher dosage than those with C/C and C/A genotypes.
出处
《中国药房》
CAS
CSCD
2013年第22期2049-2050,共2页
China Pharmacy
基金
深圳市科技计划资助项目(No.201203053)
关键词
他克莫司
基因多态性
血药浓度
剂量
Tacrolimus
Genetic polymorphism
Blood concentration
Dosage
